AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aurinia Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.49−0.02 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Aurinia Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $297.78M | $284.94M | $271.35M | $254.75M | $239.63M | $228.08M | $216.19M | $200.92M | $186.20M | $172.27M | $158.53M | $144.54M | 95.6% | +24.3% |
| License, collaboration and royalty revenue | $13.73M | $13.36M | $11.71M | $11.05M | $20.48M | $19.21M | $18.95M | – | – | – | – | – | 4.4% | -33.0% |
By region
From the segment and revenue-disaggregation notes of Aurinia Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.